Skip to main
TVTX
TVTX logo

Travere Therapeutics (TVTX) Stock Forecast & Price Target

Travere Therapeutics (TVTX) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 31%
Buy 56%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Travere Therapeutics has demonstrated strong momentum with Filspari, reporting a remarkable 37% quarter-over-quarter increase in new patient start forms for the fourth quarter of 2024, indicating robust prescribing activity. The company has revised its total net sales projection for 2025 upward to $339.9 million, reflecting growing confidence in Filspari's potential as it prepares for key regulatory events and market expansions, particularly with FSGS. Additionally, ongoing commercial launches in Europe and the anticipated impact of updated KDIGO guidelines are expected to enhance market opportunities for Filspari, further solidifying positive financial expectations for Travere Therapeutics.

Bears say

The negative outlook on Travere Therapeutics's stock is primarily driven by several key risks that jeopardize the company’s financial performance and growth potential. Firstly, the potential failure to secure regulatory approval for pegtibatinase, along with the possibility of clinical trial failures, raises significant concerns about the viability of its drug pipeline. Additionally, the competitive landscape for commercial products like FILSPARI introduces uncertainty regarding market penetration and profitability, compounded by operational challenges such as the company's voluntary enrollment pause in trials and ongoing needs for additional funding.

Travere Therapeutics (TVTX) has been analyzed by 16 analysts, with a consensus rating of Buy. 31% of analysts recommend a Strong Buy, 56% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Travere Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Travere Therapeutics (TVTX) Forecast

Analysts have given Travere Therapeutics (TVTX) a Buy based on their latest research and market trends.

According to 16 analysts, Travere Therapeutics (TVTX) has a Buy consensus rating as of Jul 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $33.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $33.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Travere Therapeutics (TVTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.